Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BM
The experimentally established mechanism targets of Amantadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.72 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.72 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.72 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.72 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.72 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.72 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.72 |
| ▸ | THRB | P10828 | 2/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.72 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | STAT6 | P42226 | 1/20 | 0.72 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.72 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amantadine SCHEMBL15015750 | 0.92 | THRB (0.71) | THRBCYP2C9LMNATSHRSLC22A2 | |
| Amantadine SCHEMBL20357994 | 0.90 | THRB (0.68) | THRBCYP2C9LMNATSHRSLC22A2 | |
| Amantadine SCHEMBL27677379 | 0.90 | THRB (0.68) | THRBCYP2C9LMNATSHRSLC22A2 | |
| Amantadine SCHEMBL15015696 | 0.90 | LMNA (0.70) | THRBCYP2C9LMNATSHRSLC22A2 | |
| Amantadine SCHEMBL15016083 | 0.87 | LMNA (0.67) | THRBCYP2C9LMNATSHRSLC22A2 | |
| Amantadine SCHEMBL20357966 | 0.87 | THRB (0.65) | THRBCYP2C9LMNATSHRSLC22A2 | |
| Amantadine SCHEMBL3761365 | 0.85 | THRB (1.00) | THRBCYP2C9LMNATSHRSLC22A2 | |
| Amantadine SCHEMBL31756726 | 0.85 | THRB (1.00) | THRBCYP2C9LMNATSHRSLC22A2 | |
| Amantadine SCHEMBL29011286 | 0.85 | GRIN1 (0.87) | THRBCYP2C9LMNATSHRSLC22A2 | |
| Amantadine SCHEMBL15672299 | 0.85 | GRIN1 (1.00) | THRBCYP2C9LMNATSHRSLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1789380-A1 | AMINO ADAMANTANE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | Justus-Liebig-Universität Giessen (DE) | 2007-05-30 | — | — | EP | claimed |
| WO-2006010362-A1 | AMINO ADAMANTANE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) | 2006-02-02 | — | — | WO | claimed |
| CN-119661366-A | Preparation method and application of amantadine carbonate | 李果 | 2025-03-21 | — | — | CN | disclosed |
| CN-101823775-A | Method for treating amantadine waste water through crystallization | UNIV SHENYANG JIANZHU | 2010-09-08 | — | — | CN | disclosed |
| US-20090246233-A1 | Treatment of Gastroparesis and Nonulcer Dyspepsia With GABAB Agonists | AGI THERAPEUTICS RESEARCH LTD. | 2009-10-01 | — | — | US | disclosed |
| EP-1789380-A1 | AMINO ADAMANTANE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | Justus-Liebig-Universität Giessen (DE) | 2007-05-30 | — | — | EP | disclosed |
| EP-1675581-A1 | TREATMENT OF GASTROPARESIS AND NONULCER DYSPEPSIA WITH GABA-b AGONISTS | AGI THERAPEUTICS RESEARCH LIMITED (IE) | 2006-07-05 | — | — | EP | disclosed |
| WO-2006010362-A1 | AMINO ADAMANTANE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) | 2006-02-02 | — | — | WO | disclosed |
| US-20050090554-A1 | Administering baclofen, or a salt thereof, to relieve at least one symptom of gastroparesis other than vomiting | AGI THERAPEUTICS LTD. (IE) | 2005-04-28 | — | — | US | disclosed |
| WO-2005025559-A1 | TREATMENT OF GASTROPARESIS AND NONULCER DYSPEPSIA WITH GABAB AGONISTS | AGI THERAPEUTICS LTD. (US) | 2005-03-24 | — | — | WO | disclosed |